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ABSTRACT
Since 2014, Stony Coral Tissue Loss Disease (SCTLD) has led to mass mortality
of the majority of hard coral species on the Florida Reef Tract. Following the
successful treatment of SCTLD lesions on laboratory corals using water dosed with
antibiotics, two topical pastes were developed as vehicles to directly apply antibiotic
treatments to wild corals. These pastes were tested as placebos and with additions
of amoxicillin on active SCTLD lesions on multiple coral species. The effectiveness
of the pastes without antibiotics (placebo treatments) was 4% and 9%, no
different from untreated controls. Adding amoxicillin to both pastes signiﬁcantly
increased effectiveness to 70% and 84%. Effectiveness with this method was
seen across ﬁve different coral species, with success rates of the more effective
paste ranging from 67% (Colpophyllia natans) to 90% (Orbicella faveolata and
Montastraea cavernosa). Topical antibiotic application is a viable and effective tool
for halting disease lesions on corals affected by SCTLD.
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Beginning in 2014, a disease since named Stony Coral Tissue Loss Disease (SCTLD)
appeared on scleractinian corals near Miami, Florida (Precht et al., 2016). It has since
spread throughout the Florida Reef Tract with a spatial pattern following a contagious
model of transmission (Muller et al., 2020). Beginning in 2017, SCTLD began appearing in
other regions of the Caribbean (Alvarez-Filip et al., 2019; Weil et al., 2019). The disease
is known to affect over 20 species of corals and is characterized by multifocal acute
lesions that in some cases are preceded by a bleaching margin (FKNMS/DEP, 2018). It is
highly virulent, and capable of being transmitted by physical contact and also through
seawater (Aeby et al., 2019). Progression of lesions across a colony is rapid compared
to most other coral diseases, and in the majority of cases, lesions result in complete colony
mortality. Ecosystem impacts are substantial and include signiﬁcant decreases in coral
cover, colony density and biodiversity (Precht et al., 2016; Walton, Hayes & Gilliam, 2018).
Fulﬁllment of Koch’s postulates for coral diseases is particularly difﬁcult (Richardson,
1998) and deﬁnitive pathogen identiﬁcation for SCTLD has not been successful.
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However, efforts to identify the cause of the epidemic are ongoing and have identiﬁed
differences in bacterial communities between healthy and diseased corals (Meyer et al.,
2019; Rosales et al., 2020). Additionally, early laboratory work noted that water dosing
with antibiotics resulted in disease cessation (O’Neil, Neely & Patterson, 2018; Aeby et al.,
2019), suggesting a bacterial component. Though both amoxicillin and ampicillin
water baths were effective, ampicillin was preferred as it dissolved more easily. Follow-up
efforts by NOAA’s Coral Disease and Health Consortium (C. Woodley, 2018–2020,
personal communication) developed a modiﬁed dental paste that could be topically applied
to disease margins; this product is still in use by laboratories and aquariums treating
SCTLD-affected corals (O’Neil, Neely & Patterson, 2018). However, the use of the modiﬁed
dental paste requires patting the coral dry and maintaining it in low water ﬂow for 18 h,
making it impracticable on wild corals. To resolve this, partnerships between the authors,
the Florida Aquarium’s Center for Conservation, and a pharmaceutical formulation
and manufacturing company (Ocean Alchemists LLC and CoreRx Pharmaceuticals) led
to the development of topical pastes that could be used in ﬁeld applications to
determine whether SCTLD could be stopped on in situ colonies with active lesions.
This study compared the effectiveness of untreated controls, two placebo topical pastes
(here termed Base 2b and New Base), and both pastes with amoxicillin additives to
determine whether disease lesions could be halted.

MATERIALS AND METHODS
Corals affected with SCTLD were selected for treatment at Sand Key (Fig. 1) in the
lower Florida Keys (permit from Florida Keys National Marine Sanctuary #2019-115).
Colonies were located within a 4,000 m2 area ranging in depth from 5 to 13 m.
A total of 61 corals representing ﬁve species were selected for experimental treatment in
October 2019. Each colony had between 1 and 12 active SCTLD lesions, and a total of
171 lesions were treated (Table 1). Due to the limited availability of suitable colonies
and the varying number of lesions on each, the numbers of colonies and lesions were
not the same across species and treatments. Three species (Colpophyllia natans,
Montastraea cavernosa, Orbicella faveolata) were represented across all treatments.
C. natans has been identiﬁed as a highly susceptible species, while M. cavernosa and
O. faveolata have been classed as intermediately susceptible species (FKNMS/DEP, 2018).
Two additional highly susceptible species, Diploria labyrinthiformes and Pseudodiploria
strigosa, were compared between just two treatment types.
Selected colonies all had visibly active and rapidly progressing SCTLD disease lesions as
identiﬁed by at least 1 cm of bright white bare skeleton adjacent to live tissue. Colonies had
maximum linear dimensions ranging from 12 to 432 cm. Each colony was tagged and
mapped for future identiﬁcation. A masonry nail (2″) was hammered into each lesion to
identify the location and progression of the disease margin.
Colonies were randomly assigned one of ﬁve treatments.
1. Control: colony was tagged and nails were afﬁxed at the disease margin, but no
treatment was applied.
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2. “Base 2b” Placebo: a proprietary (CoreRx/Ocean Alchemists) silicone-based paste that
included polymers to mimic coral mucus consistency was applied directly to the disease
margin(s).
3. Base 2b + Amoxicillin: the silicone-based paste was hand mixed with powdered
amoxicillin (sourced from Phytotechnology Laboratories. 98.1% purity) in an 8:1 (base:
amoxicillin) by weight ratio. The paste included time-release products that regulated
release of the amoxicillin over a 3-day time period.
4. “New Base” Placebo: a proprietary (CoreRx/Ocean Alchemists) biodegradable
hydrophobic ointment designed to hold and release antibacterial compounds.
5. New Base + Amoxicillin: the New Base Placebo was mixed with powdered amoxicillin in
an 8:1 by weight ratio. Release modiﬁers in the base facilitated amoxicillin release over
3 days.
Treatments were prepared less than 6 h before application by mixing amoxicillin into
treatments 3 and 5, and by packing treatments 2–5 into 60cc catheter syringes. At each
affected coral, a treatment was squeezed from the syringe and pressed by hand onto
the length of the disease margin in a band approximately 1 cm wide. Half (0.5 cm) of
the application overlaid and anchored on to the dead skeleton while 0.5 cm covered
adjacent live tissue. If there were multiple lesions on a coral, they all received the same
treatment. The amount of treatment product applied to each coral varied with the number
and the size of lesions but averaged 12.3 mL (±11.2 mL SD) per treated coral. Among
the 28 amoxicillin-treated colonies, an average of 1.6 g (±1.7 g SD) of amoxicillin was
applied for a total application of 39.6 grams at the site.
Corals were monitored 4 weeks after the initial treatment. At each coral, the number
of effective and ineffective treatments were tallied. Photographs were also taken and
arranged so that before and after photos of each lesion could be compared (representative
samples: Fig. 2). All analyses were based on the photographic comparisons because
more lesions could be positively identiﬁed. Effectiveness was deﬁned as the cessation of
disease progression at the treatment line. Ineffectiveness was deﬁned as the lesion
continuing unimpeded across the colony. After the 1-month monitoring, all active lesions
on all surviving corals were treated with Base 2b + Amoxicillin. A total of 55 retreated
lesions (5 C. natans, 19 M. cavernosa and 31 O. faveolata) were reassessed 2 months later
for effectiveness.
The proportion of halted lesions was compared across treatments using Fisher’s exact
test (a = 0.05), which is suitable for unequal as well as small sample sizes. Lesions on the
same coral were considered independent because:
1. Microbiome studies of SCTLD colonies identify healthy regions of tissue adjacent to
diseased regions (Meyer et al., 2019).
2. Field observations of lesion development on individual colonies over time note
asynchronous appearance, suggesting independent development.
Additional analyses that do not assume lesion independence were conducted by
comparing the proportion of halted lesions on each colony across species and treatments.
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Figure 1 Location of research site. Map showing research site (star) at Sand Key, Florida Keys. Grey
indicates land, pink represents patch reefs, and red indicates spur and groove reefs.
Full-size  DOI: 10.7717/peerj.9289/ﬁg-1

Table 1 Sample sizes for each treatment. Number of colonies (A) and lesions (B) receiving each
treatment (“Amoxi” represents addition of powdered amoxicillin). Four-letter species codes represent:
Colpophyllia natans (CNAT), Montastraea cavernosa (MCAV), Orbicella faveolata (OFAV), Diploria
labyrinthiformes (DLAB) and Pseudodiploria strigosa (PSTR).
Control

New Base
Placebo

New Base +
Amoxi

Base 2b
Placebo

Base 2b +
Amoxi

CNAT

2

2

2

2

1

MCAV

2

3

2

3

5

OFAV

2

3

3

5

5

DLAB

5

4

PSTR

4

6

A
#Colonies

B
#Lesions
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CNAT

8

2

7

8

3

MCAV

4

6

4

9

9

OFAV

4

19

12

14

23

DLAB

8

8

PSTR

8

15
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Figure 2 Examples of treated SCTLD lesions. Representative photos of placebo treatments and
amoxicillin treatments. Species codes are: PSTR, Pseudodiploria strigosa; DLAB, Diploria labyrinthiformes; OFAV, Orbicella faveolata. Photos show the corals immediately before treatment was
applied, immediately after treatment was applied, and 1 month after treatment. The exception is the “1
month” photo of the placebo DLAB ( ), which was taken 2 weeks after treatment; the colony was totally
dead at 1 month.
Full-size  DOI: 10.7717/peerj.9289/ﬁg-2
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Figure 3 Effectiveness of treatments in halting disease lesions. Number of halted (A) and active
(B) lesions for each treatment type 1 month after treatments. Colors/patterns represent different species.
Total percentage of lesions that halted under each treatment regime are shown above the halted lesion
bars.
Full-size  DOI: 10.7717/peerj.9289/ﬁg-3

Sample sizes were small, (between one and six colonies per species per treatment), unequal,
and did not always pass Shapiro-Wilk normality or Brown-Forsythe equal variance tests.
Therefore, comparisons were conducted using t-tests when assumptions were met and
Mann-Whitney Rank Sum Tests when they were not.

RESULTS
The percentage of effective lesion treatments varied by treatment type and, to some
extent, species (Fig. 3). Across all species, 0% of the control (untreated) lesions halted.
Overall effectiveness of New Base Placebo and Base 2b Placebo treatments on lesions were
4% (1/27) and 9% (4/47) respectively. When amoxicillin was added, effectiveness increased
to 70% (16/23) for the New Base and 84% (49/58) for the Base 2b.
Because the treatments varied in the number of lesions on different species, analyses
were further broken down by species (Table 2). C. natans treatments exhibited the least
difference between placebo and amoxicillin treatments; when amoxicillin was added to
both the New Base and the Base 2b, effectiveness increased by 29%. On O. faveolata,
effectiveness increased 78% when amoxicillin was added to the New Base and 91% when
Neely et al. (2020), PeerJ, DOI 10.7717/peerj.9289
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Table 2 Statistical comparisons of lesion treatment effectiveness. Number of effective and ineffective
lesion treatments for each species and treatment type and p-values from Fisher’s exact test comparisons
between treatments for each species. Statistically signiﬁcant results are highlighted in green.
Control

New Base
Placebo

New Base +
Amoxi
2:5 (29%)

Base 2b
Placebo

Base 2b +
Amoxi

CNAT
Effective: ineffective

0:8 (0%)

0:2 (0%)

Control

–

N/A (both zero) 0.2

3:5 (38%)

2:1 (67%)

0.2

0.055

New Base Placebo

N/A (both zero) –

1

1

0.4

New Base + Amoxi

0.2

1

–

1

0.5

Base 2b Placebo

0.2

1

1

–

0.54

Base 2b + Amoxi

0.055

0.4

0.5

0.54

–
21:2 (91%)

OFAV
Effective: ineffective

0:4 (0%)

1:18 (5%)

10:2 (83%)

0:14 (0%)

Control

–

1

0.008

N/A (both zero) <0.001

New Base Placebo

1

–

<0.001

1

<0.001

New Base + Amoxi

0.008

<0.001

–

<0.001

0.594

Base 2b Placebo

N/A (both zero) 1

<0.001

–

<0.001

Base 2b + Amoxi

<0.001

<0.001

0.594

<0.001

–

0:4 (0%)

0:6 (0%)

4:0 (100%)

0:9 (0%)

8:1 (89%)

Control

–

N/A (both zero) 0.029

New Base Placebo

N/A (both zero) –

0.005

N/A (both zero) 0.001

New Base + Amoxi

0.029

–

0.001

1

Base 2b Placebo

N/A (both zero) N/A (both zero) 0.001

–

<0.001

Base 2b + Amoxi

0.007

0.001

1

<0.001

–

Effective: ineffective

–

–

–

1:7 (13%)

7:1 (88%)

Base 2b Placebo

–

–

–

–

0.001

Effective: ineffective

–

–

–

0:8 (0%)

11:4 (73%)

Base 2b Placebo

–

–

–

–

0.001

MCAV
Effective: ineffective

0.005

N/A (both zero) 0.007

DLAB

PSTR

added to the Base 2b. On M. cavernosa, the addition of amoxicillin increased effectiveness
by 100% in New Base and 89% in Base 2b as compared to their placebo counterparts.
Because of species rarity, D. labyrinthiformes and P. strigosa lesions treatments were
restricted to Base 2b Placebo and Base 2b + Amoxicillin treatments; effectiveness was 0%
with placebo treatments, while 88% (7/8: D. labyrinthiformes) and 73% (11/15: P. strigosa)
of amoxicillin treated lesions were effective.
Fisher’s exact tests identiﬁed similarities and differences among treatments (Table 2).
On O. faveolata, M. cavernosa, and C. natans, there were no signiﬁcant differences between
untreated controls, New Base Placebo and Base 2b Placebo. On C. natans, there were
no signiﬁcant differences between any treatments (controls, placebos and non-placebos),
although the p-value between untreated controls and Base 2b + Amoxicillin was 0.055.
Neely et al. (2020), PeerJ, DOI 10.7717/peerj.9289
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Figure 4 Percentage of effective lesion treatments per colony. The average percentage of lesion
treatments that were effective on each coral colony, separated by species and treatment type. Error bars
indicate standard error.
Full-size  DOI: 10.7717/peerj.9289/ﬁg-4

On both O. faveolata and M. cavernosa, there were signiﬁcant differences between controls
and both amoxicillin products. There were also signiﬁcant differences between both placebo
bases and their amoxicillin counterparts. There were no signiﬁcant differences in effectiveness
between New Base + Amoxicillin and Base 2b + Amoxicillin. On D. labyrinthiformes
and P. strigosa, effectiveness of Base 2b + Amoxicillin was signiﬁcantly higher than the
Base 2b Placebo (p = 0.001). Across ﬁve of the six tested species, the percentage of lesions
halted using both amoxicillin bases was between 73% and 90%. However, amoxicillin
treatments on C. natans were less effective, particularly with the New Base (29%).
Treatments were also analyzed at a colony level in consideration that host genotype
may play a role in treatment effectiveness. The percentage of halted lesions on each
colony was compared across treatments for each species (Fig. 4). For all species, the
percentage of halted lesions was higher for New Base + Amoxicillin or Base 2b + Amoxicillin
treatments than for placebo-treated colonies and controls. Statistically, ANOVA on Rank
tests across all treatment types had extremely low power and could not detect post-hoc
differences between treatments by species (Table 3). However, individual comparisons did
detect signiﬁcant differences on P. strigosa between Base 2b + Amoxicillin and Base 2b
Placebo (Mann-Whitney Rank Sum Test: p = 0.038), and also on O. faveolata between Base
2b + Amoxicillin compared to both Base 2b Placebo and New Base Placebo (Mann-Whitney
Rank Sum Test: p = 0.008 and t-test: p < 0.001 respectively).
One month after treatment, one of the control colonies and six of the Base 2b Placebo
colonies had died completely. Of the surviving colonies, new lesions had developed
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Table 3 Statistical comparisons of the percentage of lesions halted on each coral colony. Average
percentage (± standard error) of halted lesions on each coral colony by treatment are presented for each
species. Comparisons for each treatment show p-values from two-tailed t-tests where normality and
equal variance assumptions were met, and from Mann-Whitney Rank Sum Tests where they were not.
Statistically signiﬁcant results are highlighted in green.
Control

New Base
Placebo

New Base +
Amoxi

Base 2b
Placebo

Base 2b +
Amoxi

0±0

0±0

58 ± 42

21 ± 21

67 ± N/A

Control

–

1

–

0.667

N/A

New Base Placebo

1

–

0.333

0.667

N/A

New Base + Amoxi

0.333

0.333

–

0.667

N/A

Base 2b Placebo

0.667

0.667

0.667

–

N/A

Base 2b + Amoxi

N/A

N/A

N/A

N/A

–

0±0

3±3

67 ± 33

0±0

90 ± 6

Control

–

0.495

0.136

1

0.095

New Base Placebo

0.495

–

0.24

0.57

<0.001

New Base + Amoxi

0.136

0.24

–

0.143

0.399

Base 2b Placebo

1

0.57

0.143

–

0.009

Base 2b + Amoxi

0.095

<0.001

0.399

0.009

–

Average % (±SE)

0±0

0±0

100 ± 0

0±0

80 ± 20

Control

–

1

0.333

1

0.19

New Base Placebo

1

–

0.33

1

0.19

New Base + Amoxi

0.333

0.33

–

0.2

0.857

Base 2b Placebo

1

1

0.2

–

0.07

Base 2b + Amoxi

0.19

0.19

0.857

0.07

–

Average % (±SE)

–

–

–

20 ± 20

75 ± 25

Base 2b Placebo

–

–

–

–

0.135

Average % (±SE)

–

–

–

0±0

81 ± 16

Base 2b Placebo

–

–

–

–

0.038

CNAT
Average % (±SE)

OFAV
Average % (±SE)

MCAV

DLAB

PSTR

on: 40% of the controls, 50% of the New Base placebo, 29% of the Base2b placebo, 29% of
the New Base + Amoxicillin and 33% of the Base2b + Amoxicillin colonies. Failed and
new lesions from all surviving colonies were treated with Base 2b + Amoxicillin. Fifty-ﬁve
of those retreatments were re-surveyed after 2 months; 80% of C. natans lesions, 77% of
O. faveolata lesions and 58% of M. cavernosa lesions had halted.

DISCUSSION
Past uses of antibiotics on diseased corals have included utilization as a diagnostic tool to
help identify bacteria as a presumptive pathogen in white band disease (Kline & Vollmer,
2011; Sweet, Croquer & Bythell, 2014) as well as water dosing to halt SCTLD lesion
Neely et al. (2020), PeerJ, DOI 10.7717/peerj.9289
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progression in laboratory and aquarium work (C. Woodley, K. O’Neil & C. Lewis,
2018–2020, personal communication). The use of skin wound treatment patches
containing antiseptics, antioxidants and/or antibiotics have also shown promise in helping
mechanically damaged corals to heal (Contardi et al., 2020). However, the results presented
here represent the ﬁrst known use of topical antibiotics as a disease treatment tool to
preserve wild populations. Effectiveness of placebos was no greater than for untreated
controls, but the addition of amoxicillin signiﬁcantly increased the percentage of lesions
halted.
Antibiotic application was successful at halting lesions on all tested species, but
effectiveness on C. natans was lower, particularly for the New Base + Amoxicillin
treatment. We suggest that the deep polyp grooves of C. natans create gaps where the
treatment is not in contact with coral tissue. Divers noted that the New Base had poorer
adherence to the coral colonies than the Base 2b, which may have been particularly
pronounced in the highly rugose C. natans, thus creating ineffective treatment barriers.
Careful application into grooves to ensure physical contact with the coral tissue is
suggested.
Antibiotic effectiveness is likely to remain localized within the region of application
rather than spreading throughout the colony; this was evidenced by the appearance of
new lesions on some amoxicillin-treated corals. To minimize mortality, coral colonies
required a 1-month revisitation in order to retreat any failed margins and to treat any new
lesions. Longer-term studies are recommended and currently underway to determine
appropriate visitation intervals and long-term maintenance requirements. Physiological
studies to determine the spread of the amoxicillin throughout the colony and the
mechanism for effectiveness are also recommended.
Treatment of SCTLD-affected colonies using topical amoxicillin paste is an option
for SCTLD disease intervention. The methodology has already been utilized to save
laboratory and aquaria corals (Florida Aquarium’s Center for Conservation, Keys Marine
Laboratory, Frost Museum of Science), in-water nursery corals (Coral Restoration
Foundation and Florida Keys National Marine Sanctuary), corals targeted for assisted
reproduction efforts (Mote Marine Laboratory), and the preservation of over 2,000 large
reef-building corals on the Florida Reef Tract (Nova Southeastern University, Harbor
Branch Oceanographic Institute). Such actions have been and should continue to be
weighed in a risk management scenario that considers unknown factors such as impacts
on the treated corals’ microbiomes as well as potential antibiotic resistance. Though
requiring an investment of time and resources for initial treatment and monitoring, topical
antibiotic treatment is a viable tool for preserving high-value corals.

CONCLUSIONS
Topical amoxicillin treatments successfully arrested disease lesion progression on multiple
species of stony corals affected by SCTLD. As this disease spreads throughout currently
affected reefs as well as new regions of the Caribbean, this type of in-water intervention
is an option to be considered within management response strategies. Follow-up
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studies on the physiological mechanisms, potential risks and long-term trajectory of
treated corals are recommended.
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